Major Sponsors:

t.b.a.

Conference Topics:

The International Neuro4D Conference is a smaller (max. 100 participants) and highly interactive event focused on Neuro Degenerative Disease Drug Discovery. We are inviting drug discovery companies, service and technology providers, and academic innovators in the field of proteopathic neurodegenerative diseases.

Neuro4D brings a limited number of distinguished industry and academic speakers, poster presenters and delegates in neurodegenerative disease in direct contact, and creates lively discussions about drug discovery efforts for two full days, in a stimulating and enjoyable setting. Academic research leaders outline recent insights into the complex disease mechanisms and new pharmaceutical action modes. Biotech and international pharmaceutical companies present their developments for new treatment options and outline advantages and disadvantages of disease models and screening technologies used for compound selection and optimization. Service and technology providers present their platforms and show examples of how their services contribute to the discovery of new drug candidates. By the end of the conference, all participants got to know each other, seeding many productive collaborations in the past.

During Neuro4D 2025 we will focus on Alzheimer’s disease again, however, not excluding other neurodegenerative disease developments. We will look at the potential and ongoing initiatives using new pharmaceutical modalities like PROTACs, molecular glues and other direct target modulating technologies. As in recent years, the event will be located in the Atrium Hotel and the inspiring environment of Mainz, Germany, with easy access to Frankfurt international airport. The conference will stick to the successful session format and chairperson leadership. Each speaker has 15 min for presentation and Q&A, and will participate in a podium discussion with all speakers at the end of each session.

Online Registration Fee for 2025 includes conference hotel accommodation from Sunday, May 18 to Tuesday, May 20 for all delegates, food and drinks during the entire two days of the event, joint social activities, and the highly praised interactive conference dinner party on Monday evening.

Each registered delegate is entitled and encouraged to show a poster during the conference. The deadline for poster abstract (max. 300 words) submission 2025, is April 14! They will be checked and confirmed ASAP. Accepted abstracts of participating delegates will be published in the program. Please submit your abstracts in MS Word, or as Email text to the organizer: info@bioexpert.biz.

Poster boards have portrait orientation with a width of 118.5 cm and a height of 146 cm. Posters must have a maximum size of A0 (84 × 119 cm). Poster presenters are requested to be at their posters during dedicated breaks.

All presentations incl. Q&A will be 15 min. A chairman-led podium discussion of 15 min with all speakers of the past session will follow. Chairmen will introduce their session subject with a 30 min presentation.

Conference Venue:

Atrium Hotel Mainz
Flugplatzstraße 44
55126 Mainz
Germany
Tel.: +49 6131 80 15 0
info@atrium-mainz.de
www.atrium-mainz.de

Organizer:

Dr. Andreas Köpke (bioExpert)
Tel: +49 6136 957 3000
info@bioexpert.biz

Draft Program:

2024 Conference Program (PDF)
last update: December 20, 2024

Topics Highlights:

In 2024 we saw an increased number of antibody approvals for Alzheimer’s disease, finally also in Europe! Antibodies against soluble misfolded amyloid-β aggregates have shown preservation of cognition, confirming the crucial role of soluble misfolded protein aggregates in neurodegeneration. Furthermore, biomarker values were improved and plaques were reduced.

The prion-like properties of protein aggregates in neurodegenerative diseases asks for multiple strategies to reduce brain burden of these toxic structures. Multiple new pharmacological interventions reducing protein monomers, or aggregates, and refolding misfolded toxic protein aggregates will be presented.

We will hear about new diagnostic technologies, providing new insights into disease progression and the healthy situation. Clinical biomarker detections and result observations will be discussed.

In the final clinical session, we will listen to clinical study designs, study results, and observed side effects. As always, we will discuss recent developments, clinical outcomes and the benefit for patients and caregivers in a podium discussion at the end of the meeting.

Sponsors:

t.b.a

Target Audience:

• Drug discovery experts from biotech and pharmaceutical industry
• Academic experts in proteopathic neurodegenerative diseases interested in drug discovery
• Service providers of technologies, analytical tools, and models for neurodegenerative diseases
• Pharma strategists and investors interested in the field and prepared to learn and fund the most innovative approaches
• PhDs looking for new positions in the field

Advisory Committee:

Rakez Kayed, UTMB, Galveston, USA
Neil Cashman, ProMIS, Vancouver, Canada
Oliver Peters, Clinic for Psychiatry and Psychotherapy, Frankfurt-Oder, Germany
Roger Sher, Stony Brook University, USA

Registration:

Corporate*	Academic*
1590 € (additional: 1090 €)	790 €	Early Bird (before March 15)
1990 € (additional: 1290 €)	990 €	Regular (until May 15)
*all registrations include accommodation in the conference hotel from Sun May 18 to Tue May 20 2025, all meals and drinks during the conference, and the conference dinner on Monday night. Add. Nights in single superior room in the conference hotel, incl. breakfast: 150 € On Site Registration: at regular price, incl. meals and drinks, but excl. accommodation All prices: plus 19% German VAT, mandatory for events held in Germany
Early Bird until and including March 15th, 2025 » register now